ES2061500T3 - Diagnosis y vacunas de la hepatitis delta su preparacion y uso. - Google Patents

Diagnosis y vacunas de la hepatitis delta su preparacion y uso.

Info

Publication number
ES2061500T3
ES2061500T3 ES87305391T ES87305391T ES2061500T3 ES 2061500 T3 ES2061500 T3 ES 2061500T3 ES 87305391 T ES87305391 T ES 87305391T ES 87305391 T ES87305391 T ES 87305391T ES 2061500 T3 ES2061500 T3 ES 2061500T3
Authority
ES
Spain
Prior art keywords
products
delta
orf5
vaccines
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87305391T
Other languages
English (en)
Other versions
ES2061500T5 (es
Inventor
Michael Houghton
Kang-Sheng Wang
Qui-Lim Choo
Amy Joan Weiner
Lacy Rasco Overby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26732482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2061500(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of ES2061500T3 publication Critical patent/ES2061500T3/es
Application granted granted Critical
Publication of ES2061500T5 publication Critical patent/ES2061500T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5765—Hepatitis delta antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10111—Deltavirus, e.g. hepatitis delta virus
    • C12N2760/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/823—Lower fungi, e.g. mold
    • Y10S530/824—Yeasts
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

EL GENOMA ENTERO DEL VIRUS DE LA HEPATITIS D HA MOSTRADO INDICIOS DE SER UN FILAMENTO SIMPLE CIRCULAR DE ARN DE 1679 BASES. VARIAS LECTURAS ABIERTAS DEL ENTRAMADO EN LOS DOS, EL GENOMICO Y EL FILAMENTO COMPLEMENTARICO INDICAN POSIBLES PRODUCTOS PROTEICOS. LOS PRODUCTOS CODIFICADOS EN LA LECTURA DEL ENTRAMADO ABIERTO, ORF5, SON IDENTIFICADOS COMO POLIPEPTIDOS VIRALES P24 DELTA Y P27 DELTA, DE LOS CUALES LOS ANTIGENOS NUCLEARES DELTA EN HIGADO INFECTADO CON HDV ESTAN COMPRENDIDOS. ESTOS PRODUCTOS TAMBIEN COMO OTROS EN ORF5 1,2,6 Y 7 ESTAN PRODUCIDOS EN SISTEMAS DE EXPRESION RECOMBINANTE. LOS PRODUCTOS ORF5 EN PARTICULAR SE USAN NORMALMENTE PARA DIAGNOSTICO Y VACUNAS DE HDV.
ES87305391T 1986-06-17 1987-06-17 Diagnosis y vacunas de la hepatitis delta, su preparacion y uso. Expired - Lifetime ES2061500T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87533786A 1986-06-17 1986-06-17
US5399187A 1987-05-22 1987-05-22

Publications (2)

Publication Number Publication Date
ES2061500T3 true ES2061500T3 (es) 1994-12-16
ES2061500T5 ES2061500T5 (es) 2003-05-16

Family

ID=26732482

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87305391T Expired - Lifetime ES2061500T5 (es) 1986-06-17 1987-06-17 Diagnosis y vacunas de la hepatitis delta, su preparacion y uso.

Country Status (7)

Country Link
US (5) US5378814A (es)
EP (1) EP0251575B2 (es)
JP (4) JP2661044B2 (es)
CA (1) CA1338800C (es)
DE (1) DE3788902T3 (es)
ES (1) ES2061500T5 (es)
HK (1) HK102595A (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2061500T5 (es) * 1986-06-17 2003-05-16 Chiron Corp Diagnosis y vacunas de la hepatitis delta, su preparacion y uso.
US4962037A (en) * 1987-10-07 1990-10-09 United States Of America Method for rapid base sequencing in DNA and RNA
IT1241003B (it) * 1990-11-05 1993-12-27 Sorin Biomedica Spa Procedimento per la purificazione di un polipeptide ricombinante hdag equivalente, polipeptide hdag equivalente e saggi immunologici che lo utilizzano
IT1255660B (it) * 1992-06-08 1995-11-09 Sorin Biomedica Spa Composizioni stabilizzate di hdag.
US5445932A (en) * 1992-11-17 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Method for detection of a new marker associated with hepatitis delta virus infection
US5824507A (en) * 1994-05-20 1998-10-20 Genelabs Technologies, Inc. Hepatitis G virus and molecular cloning thereof
US7235394B1 (en) 1995-08-29 2007-06-26 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US6127116A (en) 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
EP0952982B1 (en) 1996-10-31 2003-12-03 Biogen, Inc. Novel hepatitis b inhibitors
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
US7049428B1 (en) 1998-03-04 2006-05-23 Washington University HCV variants
US6844171B1 (en) * 1998-07-02 2005-01-18 President And Fellows Of Harvard College Oligomerization of hepatitis delta antigen
RU2130778C1 (ru) * 1998-07-31 1999-05-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
TR200102423T2 (tr) * 1998-12-04 2002-02-21 Biogen, Inc. Peptid ligandları yoluyla bağlı birden fazla imünojenik bileşeni olan HBV çekirdek antijeni parçacıkları
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
WO2000050078A1 (en) 1999-02-26 2000-08-31 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
EP1156781B1 (en) 1999-02-26 2005-06-08 Chiron Corporation Microemulsions with adsorbed macromolecules and microparticles
DE60044125D1 (de) 1999-04-14 2010-05-20 Novartis Vaccines & Diagnostic Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren-systeme
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
CA2405502A1 (en) 2000-03-29 2001-10-04 Georgetown University Method of treating hepatitis delta viral infection
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
JPWO2002068655A1 (ja) * 2001-02-27 2004-06-24 財団法人理工学振興会 Ｄ型肝炎治療剤の探索方法
FR2830019B1 (fr) 2001-09-24 2005-01-07 Assist Publ Hopitaux De Paris Molecules d'acides nucleiques d'hdv, leurs fragments et leurs apllications
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
US7598421B2 (en) * 2002-05-08 2009-10-06 Ucl Biomedica Plc Materials for the delivery of biologically-active material to cells
JP2006500062A (ja) * 2002-09-27 2006-01-05 パウダージェクト リサーチ リミテッド 遺伝子発現のための核酸構築物
EP2263687B1 (en) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
JP5557415B2 (ja) 2003-06-02 2014-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
JP2008508320A (ja) 2004-07-29 2008-03-21 カイロン コーポレイション Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物
CA2626253A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
ES2525518T3 (es) 2005-11-01 2014-12-26 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
AU2007281934B2 (en) 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
US8063063B2 (en) * 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
ES2536426T3 (es) * 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
EP2010530A2 (en) * 2006-03-23 2009-01-07 Novartis AG Methods for the preparation of imidazole-containing compounds
US20090010948A1 (en) * 2006-12-15 2009-01-08 The University Of Hong Kong Anti-tumor vaccines delivered by dendritic cells devoid of interleukin-10
KR101621837B1 (ko) 2007-09-12 2016-05-17 노파르티스 아게 Ｇａｓ57 돌연변이 항원 및 ｇａｓ57 항체
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
EP2537857B1 (en) 2007-12-21 2017-01-18 GlaxoSmithKline Biologicals SA Mutant forms of streptolysin O
CN103897045A (zh) 2009-01-12 2014-07-02 诺华股份有限公司 抗革兰氏阳性细菌疫苗中的Cna_B结构域
CA2754592A1 (en) 2009-03-09 2010-09-16 William Henry Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions
KR20130121699A (ko) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 상호작용 혼성 비동기 컴퓨터 게임 기반구조
AU2012237295A1 (en) * 2011-04-01 2013-09-19 Novartis Ag Treatment for infection with Hepatitis B virus alone or in combination with Hepatitis Delta virus and associated liver diseases
BR112020023314A2 (pt) * 2018-05-17 2021-02-02 Universität Heidelberg método e meios para a rápida detecção de infecções por hdv
WO2025096899A1 (en) * 2023-11-02 2025-05-08 Abbott Laboratories Immunoassays and methods for diagnosing hepatitis d virus (hdv) infection
KR20250149615A (ko) * 2024-04-08 2025-10-16 주식회사 루카에이아이셀 D형 간염 항원 단백질을 포함하는 면역크로마토그래피용 테스트 스트립 및 이를 포함하는 진단용 키트

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU88258I2 (es) * 1978-12-22 1994-02-03
EP0182442B2 (en) * 1978-12-22 1996-04-03 Biogen, Inc. Recombinant DNA molecules and their method of production
DE3116882A1 (de) * 1980-06-27 1982-01-21 Univ Georgetown Stabile form des zur hepatitis b gehoerenden delta-antigens und verfahren zu seiner isolierung
EP0121303B1 (en) * 1983-03-04 1989-07-26 Noctech Limited Diagnostic agent, a process for its preparation and its use in diagnostic methods
CA1247080A (en) * 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
EP0131974A1 (en) * 1983-06-08 1985-01-23 Akzo N.V. Determination of delta-antigens in body fluids
ATE73349T1 (de) * 1984-06-18 1992-03-15 Chiron Corp Hepatitisoberflaechenantigenpartikelvakzin.
NL192267C (nl) * 1984-07-31 1997-04-03 Tno Deoxyribonucleïnezuur, micro-organisme, diagnostisch hulpmiddel voor het vaststellen van HDV infectie en gebruik daarvan.
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
ATE70308T1 (de) * 1984-09-12 1991-12-15 Chiron Corp Hybridpartikel-immunogene.
ES2061500T5 (es) * 1986-06-17 2003-05-16 Chiron Corp Diagnosis y vacunas de la hepatitis delta, su preparacion y uso.
US5225347A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors

Also Published As

Publication number Publication date
ES2061500T5 (es) 2003-05-16
DE3788902T3 (de) 2004-11-25
DE3788902D1 (de) 1994-03-10
HK102595A (en) 1995-06-30
JP2823551B2 (ja) 1998-11-11
JPH09309844A (ja) 1997-12-02
EP0251575A1 (en) 1988-01-07
JP2635018B2 (ja) 1997-07-30
US5747044A (en) 1998-05-05
CA1338800C (en) 1996-12-17
JP2810004B2 (ja) 1998-10-15
EP0251575B1 (en) 1994-01-26
US5378814A (en) 1995-01-03
JP2661044B2 (ja) 1997-10-08
JPH0848694A (ja) 1996-02-20
US5932219A (en) 1999-08-03
JPS63316796A (ja) 1988-12-26
DE3788902T2 (de) 1994-08-11
JPH0867693A (ja) 1996-03-12
US5389528A (en) 1995-02-14
EP0251575B2 (en) 2002-11-13
US5750350A (en) 1998-05-12

Similar Documents

Publication Publication Date Title
ES2061500T3 (es) Diagnosis y vacunas de la hepatitis delta su preparacion y uso.
GB2255777B (en) Indicator cells and recombinant retroviruses for use in the detection of gene sequences
DK513388D0 (da) Peptider med immunologiske egenskaber svarende til hiv-2 virus, nucleotidsekvenser, der koder for saadanne peptider, antigene og immunogene midler indeholdende saadanne peptider samt fremgangsmaade og kit til in vitro diagnose af hiv-2
DE69016956D1 (de) Rekombinantes Truthahn-Herpesvirus und davon abgeleiteter Lebendimpfstoffvektor.
DK11789D0 (da) Rekombinante vaccinia-vira
ES2029171A6 (es) Un procedimiento para preparar un polipeptido virico de hepatitis no a y no b post-transfusional (pt-nanbh)
ES2052478T1 (es) Particulas retrovirales no replicantes producidas de forma recombinante empleadas como agentes antivirales e inmunogenos.
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
PT95329A (pt) Novos isolados de hcv
ES2101388T3 (es) Antigenos sinteticos para la deteccion de anticuerpos para el virus de la hepatitis c.
FR2620459B1 (fr) Virus recombinant de la vaccine
ES2144399T3 (es) Clonado del adn de virus de anemia de los pollos.
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
BR9202024A (pt) Virus de apivox recombinante,cultura de celulas eucariotica infectadas por um virus de avipox,vacina,sequencia de transferencia e plasmideo
ATE19591T1 (de) Virus der infektioesen katzen-bauchfellentzuendung, seine herstellung und es enthaltende vakzine.
ES2061603T3 (es) Mutantes viricos de la rinotraqueitis bovina infecciosa, vacunas que los contienen, metodos para la produccion de los mismos y metodos para el empleo de los mismos.
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
DK196687A (da) Kombineret vaccine, samt fremgangsmaade til fremstilling deraf
DK8789A (da) Fremgangsmaade til fremstilling af modificerede, staerkt afsvaekkede rna-virusstammer samt vaccine og dens anvendelse
DK498387D0 (da) Virus-dna-sekvens
DK0491713T3 (da) Rubella El-peptider og C-peptider
ES2074422T3 (es) Moleculas de adn y arn del subtipo accidental del virus fsma, polipeptidos, que son codificados por estas moleculas, y su uso.
TR200102168T2 (tr) BHV-1 geni silinmiş virüs aşısı.
SE8700466D0 (sv) Vaccines against melanoma
DE69028658D1 (de) Proteine, Vakzine und Nucleinsäuren

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 251575

Country of ref document: ES